Stockscreener 앱 받기
14.42
2.10%
-0.31
시간 외 거래:
14.42
전일 마감가:
$14.73
열려 있는:
$14.81
하루 거래량:
525.77K
Relative Volume:
0.56
시가총액:
$917.07M
수익:
-
순이익/손실:
$-129.61M
주가수익비율:
-4.8274
EPS:
-2.9871
순현금흐름:
$-116.59M
1주 성능:
-14.88%
1개월 성능:
-33.97%
6개월 성능:
+3.37%
1년 성능:
+78.91%
1일 변동 폭
$14.39
$15.20
1주일 범위
$14.39
$17.67
52주 변동 폭
$7.7742
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
명칭
Jade Biosciences Inc
전화
(781) 312-3013
주소
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
14.42 | 917.07M | 0 | -129.61M | -116.59M | -2.9871 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | H.C. Wainwright | Buy |
| 2025-10-09 | 개시 | BTIG Research | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-05-07 | 개시 | Wedbush | Outperform |
| 2025-05-05 | 개시 | Stifel | Buy |
| 2025-05-02 | 개시 | TD Cowen | Buy |
| 2024-06-18 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-06-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-06-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-03-25 | 재개 | Jefferies | Buy |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-12-06 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-08-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-07-26 | 개시 | Cowen | Outperform |
| 2021-07-26 | 개시 | Evercore ISI | Outperform |
| 2021-07-26 | 개시 | Jefferies | Buy |
| 2021-07-26 | 개시 | Wedbush | Outperform |
모두보기
Jade Biosciences Inc 주식(JBIO)의 최신 뉴스
Jade Biosciences at stifel 2026 virtual immunology and inflammation forum: pipeline push - Investing.com Canada
JBIO: JADE101 leads a robust pipeline with best-in-class data and rapid path to market in IgA nephropathy - TradingView
Jade Biosciences at citigroup summit: fast-track bet on igan By Investing.com - Investing.com India
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 By Investing.com - Investing.com South Africa
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 - Investing.com
Jade Biosciences Company Profile & Introduction - moomoo.com
JADE BIOSCIENCES, INC. : CLEAR STREET RAISES TARGET PRICE TO $48 FROM $25 - moomoo.com
symbol__ Stock Quote Price and Forecast - CNN
Clear Street Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - moomoo.com
LifeSci Capital Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Jade Biosciences to Participate in Upcoming Conferences - Yahoo Finance
Jade Biosciences (JBIO) Slips 1.6% as Shares Test Key Support at $19.97Median Line - dars.gov.et
Jade (JBIO) Financial Update: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Investor Response: Shares End With Little Net Change at the CloseEarnings Season Outlook - dars.gov.et
Bio Ionic Partners with Ulta Beauty on Limited Edition Jade Dream Collection - Yahoo Finance
Jade Biosciences (NASDAQ:JBIO) Shares Gap UpWhat's Next? - MarketBeat
Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027 - Pluang
Jade Biosciences: Duration Is The Real Product (NASDAQ:JBIO) - Seeking Alpha
Jade Biosciences (JBIO) Stock Analysis Report | Financials & Insights - Benzinga España
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Stifel Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
HC Wainwright Analysts Increase Earnings Estimates for JBIO - MarketBeat
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On? - Sahm
Jade Biosciences (JBIO) Advances 2.4% to $22.89 as Buyers Defend Key Support ZoneFlat Correction - vinanet.vn
Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat
Jefferies Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - Moomoo
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX) - theglobeandmail.com
Wedbush Maintains Jade Biosciences(JBIO.US) With Buy Rating, Announces Target Price $47 - Moomoo
A Quick Look at Today's Ratings for Jade Biosciences(JBIO.US), With a Forecast Between $42 to $77 - Moomoo
Jade Biosciences Is Maintained at Buy by BTIG - Moomoo
Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research - MarketBeat
Jade Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
JBIO Q1 2026 Earnings: Wider Loss Highlights Clinical-Stage Investment CycleEarnings Growth Analysis - careplusvn.com
JBIO SWOT Analysis: Financial Challenges and Development Opportu - GuruFocus
Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside - TradingView
Wedbush raises Jade Biosciences price target on pipeline progress By Investing.com - Investing.com Australia
Wedbush raises Jade Biosciences price target on pipeline progress - Investing.com
Jade Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Jade Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Asset Growth - Kalkine Media
Jade Biosciences Q2 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Jade Biosciences' Q2 Loss Narrows - marketscreener.com
Earnings Flash (JBIO) Jade Biosciences Posts Q2 Loss $0.76 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
Jade Biosciences reports Q2 net loss $55.8M, cash $461.2M; advances JADE101 to Phase 2/3 - TradingView
Jade Biosciences (NASDAQ: JBIO) boosts cash to $461M while loss widens - Stock Titan
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Jade Biosciences reports $55.8 million Q2 net loss - Quiver Quantitative
Jade Biosciences Q2 net loss widens as costs rise - TradingView
Jade Biosciences Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Jade Biosciences (NASDAQ:JBIO) Trading 10% HigherHere's What Happened - marketbeat.com
Jade Biosciences (NASDAQ:JBIO) Shares Down 4.2%Here's What Happened - MarketBeat
Orbimed Advisors LLC Sells 346,152 Shares of Jade Biosciences, Inc. $JBIO - MarketBeat
Jade Biosciences Inc (JBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):